OQROGet OQRO Pro
Insider trade

Boston Scientific (BSX)Officer sold ~$1.69M

Joseph Michael Fitzgerald, Officer at Boston Scientific, sold ~$1.69M of Boston Scientific shares.

~$1.69M
Approx. value · 17K sh @ $99.76
208K
Holds after · shares reported
Traded
Nov 3, 2025
Filed
Nov 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  2. Aug 4, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  3. Sep 23, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  4. Sep 26, 2025FDAFDA device clearance: Radial Jaw 4 Pulmonary Biopsy Forceps
  5. Oct 9, 2025FDAFDA device clearance: Orca Air/Water and Suction Valves
  6. Oct 17, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  7. Oct 22, 2025Company filing · Form 8-K · ResultsReported its results
  8. Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, John E. Sununu informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  9. Oct 27, 2025InsiderDirector sold ~$1.01M of BSX shares in the open market
  10. Oct 28, 2025FDAFDA device clearance: TheraSphere 360™ Y-90 Management Platform
  11. Oct 28, 2025InsiderDirector sold ~$297K of BSX shares in the open market
  12. Oct 28, 2025CongressDisclosed partial sale of BSX — reported range $15,001 - $50,000
  13. Oct 30, 2025FDAFDA device clearance: Moses™ 200 D/F/L Laser Fiber (M0068130100); Moses™ 365 D/F/L Laser Fiber (M0068130110); Moses™ 550 D/F/L Laser Fiber (M0068130120)
  14. Oct 30, 2025FDAFDA device clearance: OBSIDIO™ Conformable Embolic (M0013972101010)
  15. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  16. Oct 31, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  17. Nov 3, 2025 · this disclosureInsiderOfficer sold ~$1.69M of BSX shares in the open market

What came next

  1. Nov 3, 2025Insider · 1 personInsiders: 2 sales (~$3.3M)
  2. Nov 6, 2025InsiderDirector sold ~$1.27M of BSX shares in the open market
  3. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2026 Annual Bonus Plan effective for the performance year of January 1, 2026 through December 31, 2026 (the “2026 Annual Bonus Plan”).”
  4. Nov 18, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  5. Dec 1, 2025InsiderOfficer sold ~$1.76M of BSX shares in the open market
  6. Dec 3, 2025FDARecall: Boston Scientific Coyote OVER-THE-WIRE PTA Balloon Dilation Catheter, 4F, 1) 2.5mm x120mm, 150 cm, UPM/Model No. REF H74939186251210; 2) 3.5mm x120mm, 150 cm,…
  7. Dec 16, 2025Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  8. Dec 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  9. Dec 19, 2025FDARecall: HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 6mm x 8mm; Material Number (UPN): M00553520;
  10. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 20mm x 10mm; Material Number (UPN): M00553660;
  11. Dec 19, 2025FDARecall: *HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 20mm x 10mm; Material Number (UPN): M00553560;
  12. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 6mm x 8mm; Material Number (UPN): M00553680;
  13. Dec 19, 2025FDARecall: *HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 8mm x 8mm; Material Number (UPN): M00553530;
  14. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 8mm x 8mm; Material Number (UPN): M00553690;
  15. Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  16. Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
  17. Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  18. Jan 23, 2026FDAFDA device clearance: BodyGuardian Remote Monitoring System (BGRMS v3.0)
  19. Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  20. Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

Other recent filings by Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology

The full history of Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology is on the profile page.

How this filing works

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data